Pharmacy benefit manager Express Scripts reportedly blocked 48 drugs from its formulary, according to a Fierce Pharma report.
The drugs include 22 competitors to generics, 12 that include the same active ingredient with a lower net cost and 11 that have a lower-cost brand or biosimilar alternatives.
AbbVie’s Mavyret, a pangenotypic hep C hotshot, was among the drugs marked from the list in favor of Merck & Co. and Gilead treatments.
Express Scripts reportedly issued a stern statement to some drugmakers.
“Despite promises to limit price increases, drugmakers are trying to game the market by delaying generic competition, blocking access to safe and effective biosimilars, and coyly deferring – not canceling – list-price increases,” Express Scripts said on its website. “This is why our work to expand access and maximize value is more important now than ever.”
To read the full report on Fierce Pharma, click here.
